Advertisement


Anders Widmark, MD, PhD, on Intermediate-Risk Prostate Cancer: Results From the HYPO-RT-PC Trial

2016 ASTRO Annual Meeting

Advertisement

Anders Widmark, MD, PhD, of the Umea University Hospital Oncology, discusses the early toxicity results from the phase III Scandinavian study on extreme hypofractionation vs conventionally fractionated radiotherapy for intermediate-risk prostate cancer. (Abstract LBA-5)



Related Videos

Issues in Oncology

Lia M. Halasz, MD, on Disparities in Radiotherapy Delivery

Lia M. Halasz, MD, of the University of Washington Seattle Cancer Care Alliance, summarizes a session on the uneven delivery of radiotherapy in the United States and around the world. (Scientific Session 10)

Breast Cancer

Douglas W. Arthur, MD, on Breast-Preserving Surgery: Results From NRG Oncology/RTOG 1014

Douglas W. Arthur, MD, of Virginia Commonwealth University, discusses the 3-year efficacy report from a phase II study of repeat breast-preserving surgery and 3D conformal partial breast reirradiation for in-breast recurrence. (Abstract LBA-10)

Lymphoma

Richard T. Hoppe, MD, on Lymphoma: Improving Outcomes

Richard T. Hoppe, MD, of Stanford University, summarizes a session on improving outcomes by enhancing old and new indications in follicular lymphoma and Hodgkin lymphoma. (Scientific Session 5)

Lung Cancer

Thomas J. Lynch, Jr, MD, on Personalized Care and Radiation Oncology in Lung Cancer

Thomas J. Lynch, Jr, MD, of Massachusetts General Hospital, summarizes his keynote lecture on whether we are any closer to curing lung cancer with targeted treatments. (Keynote Address 2)

Head and Neck Cancer

Joanne B. Weidhaas, MD, PhD, on Head and Neck Cancer: Results of the NRG Oncology/RTOG 0522 Study

Joanne B. Weidhaas, MD, PhD, of the University of California, Los Angeles Radiation Oncology, discusses the KRAS variant as a biomarker of cetuximab response and altered immunity in head and neck cancer. (Abstract LBA-11)

Advertisement

Advertisement




Advertisement